10x Genomics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by 10x Genomics, Inc. on October 24, 2024, with the earliest event reported on that date. The filing primarily serves to announce the Company's financial results for the quarter ended September 30, 2024, via a press release issued on October 29, 2024, and to report a change in Board composition.
Key Financial Metrics
The filing text references a press release (Exhibit 99.1) containing the financial results for the quarter ended September 30, 2024. However, the body of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these details.
Material Changes and Corporate Events
- Board Resignation: Mathai Mammen resigned as a member of the Board of Directors and the Nominating and Corporate Governance Committee, effective immediately on October 24, 2024.
- Reason for Departure: The resignation is attributed solely to professional time commitments. The filing explicitly states there is no disagreement with management, operations, financial statements, policies, or procedures.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, or management commentary within its text, deferring to the attached press release for operational details. No new risks or contingencies are disclosed in this specific report beyond the standard departure of a director.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended September 30, 2024, in the attached press release (Exhibit 99.1), as they are not listed in this summary text.
- Confirm the effective date of Mathai Mammen's resignation (October 24, 2024) and the stated reason (professional time commitments).
- Note that the financial information in this filing is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.